BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220711
DTEND;VALUE=DATE:20220714
DTSTAMP:20260515T164606
CREATED:20220330T093536Z
LAST-MODIFIED:20220623T094708Z
UID:33675-1657497600-1657756799@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy for Neurological Disorders Europe
DESCRIPTION:Accelerating Europe’s Progress in CNS Gene Therapy \nNavigating Europe-Specific Challenges & European Regulators Requirements; Optimizing Preclinical Research in Neurological Models & Revolutionizing Gene Therapy Delivery to CNS Targets in the Clinic \nAs programs advance globally\, the 3rd Annual Gene Therapy for Neurological Disorders Europe meeting is the industry’s definitive forum dedicated to showcasing the European landscape’s progress and specific regulatory challenges as they move from rare neurological disorders to targeting more common diseases including Parkinson’s\, epilepsy and neurodevelopmental disorders. \nReturning as its first in-person meeting\, with brand new speakers and companies joining the conversation\, attend alongside 100 fellow preclinical\, translational\, clinical and commercial gene therapy experts to overcome your translational challenges and improve the delivery of your gene therapy to its CNS target\, and optimize your European strategy as you move from rare to common patient populations. \nTo know more visit: https://ter.li/l4b1t3
URL:https://www.pharmajournalist.com/event/3rd-annual-gene-therapy-for-neurological-disorders-europe/
LOCATION:Paris Marriott Charles de Gaulle Airport Hotel\, Zone Hoteliere\, 5 All. du Verger\, Roissy-en-France\, 95700
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220711
DTEND;VALUE=DATE:20220714
DTSTAMP:20260515T164606
CREATED:20220412T094733Z
LAST-MODIFIED:20220412T094733Z
UID:33773-1657497600-1657756799@www.pharmajournalist.com
SUMMARY:Digital Biomarkers and Clinical Measures in Neurology Summit
DESCRIPTION:The Digital Biomarkers & Clinical Measures in Neurology Summit is the definitive industry forum sharing cross-industry insight to transform clinical development with digital data. \nFrom integrating wearable technologies\, smartphone apps\, and speech-based digital biomarkers into remote clinical research to elucidating pathways to clinical validation to establish therapeutic efficacy\, join industry experts from Merck\, Janssen\, GSK\, Sanofi\, Novartis\, Takeda\, Eli Lilly & Company\, Mitsubishi Tanabe Pharma Holdings America and many more to improve patient retention and establish efficacy with richer datasets. \nTo know more visit: https://ter.li/mk4lmh
URL:https://www.pharmajournalist.com/event/digital-biomarkers-and-clinical-measures-in-neurology-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220712
DTEND;VALUE=DATE:20220715
DTSTAMP:20260515T164606
CREATED:20220413T082618Z
LAST-MODIFIED:20220413T085216Z
UID:33780-1657584000-1657843199@www.pharmajournalist.com
SUMMARY:3rd GxP Cloud Compliance Summit
DESCRIPTION:Migrate Your GxP Regulated Applications to the Cloud with Compliance\, Security\, & Quality Assurance  \nWith hot anticipation for the FDA’s new CSA guidance\, life science companies have the opportunity to take a proactive stance in their approach to the new methodologies. In the climate of this exciting new era of computer systems validation\, join over 100 Life Science\, IT & Quality professionals at the 3rd GxP Cloud Compliance Summit. \nEmulating on 2021’s success\, the 3rd GxP Cloud Compliance Summit is excited to return in July\, for the first time in person! \nThis is your only opportunity to develop and implement a practical roadmap to migrate your GxP regulated applications to the cloud with real-life insights from regulatory\, security and quality experts from leading life science companies\, as well as cloud providers\, auditors\, and industry regulators. \nWith the FDA strongly advising life science organizations to start getting ready for CSA now\, join us in July to discover how your business can get ahead and simplify the transition process. \nTo know more visit: https://ter.li/uichgz
URL:https://www.pharmajournalist.com/event/3rd-gxp-cloud-compliance-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220712
DTEND;VALUE=DATE:20220715
DTSTAMP:20260515T164606
CREATED:20220427T072259Z
LAST-MODIFIED:20220427T072259Z
UID:33913-1657584000-1657843199@www.pharmajournalist.com
SUMMARY:BCMA Targeted Therapies Summit
DESCRIPTION:With the undeniable excitement in the BCMA field over the past few months\, the BCMA-Targeted Therapies Summit returns to the space to equip you with the knowledge and connections to revolutionize your BCMA-centered pipeline. \nPick the brains of 90+ academic and industry pioneers at the first physical edition of the only meeting dedicated to supercharging transformative next generation BCMA-targeted therapies into the clinic\, navigating the complex landscape and optimizing clinical strategy to revolutionize treatment of multiple myeloma and beyond. \nHear from leading speakers including: \n\n\n\nSuzette Girgis\, Senior Director & Head of Clinical Pharmacology & Hematologic Malignancies\, Johnson & Johnson Services\nEric Fedyk\, Global Program Leader of BCMA Assets\, 2seventy bio\nDavid DiLillo\, Director\, Immuno-Oncology\, Regeneron\nBrandon Kremer\, Group Senior Medical Director\, Clinical Development Lead\, GlaxoSmithKline\nNathan Martin\, Translational Scientist & Project Lead\, Bristol Myers Squibb\nMike Damore\, Director & Lead – Translational Oncology\, Pfizer\nChetasi Talati\, Medical Director\, AbbVie\nDexiu Bu\, Senior Principle Scientist\, CART group\, Immuno-Oncology & Hematology\, Novartis\nFaiza Zafar\, Senior Medical Science Liaison\, Legend Biotech\n\n\n\nTake a look at the full event guide to learn more.
URL:https://www.pharmajournalist.com/event/bcma-targeted-therapies-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220713
DTEND;VALUE=DATE:20220715
DTSTAMP:20260515T164606
CREATED:20220323T103153Z
LAST-MODIFIED:20220324T101902Z
UID:33612-1657670400-1657843199@www.pharmajournalist.com
SUMMARY:Advanced Wound Care Summit
DESCRIPTION:The Advanced Wound Care Innovation Summit is the first industry-led forum focused on delivering innovative wound care treatments to patients. Expect to hear from\, and discuss with\, world leaders of wound care research who are driving the development of novel biomaterials\, remote-monitoring devices\, and digital health management solutions. \nFind out how C-level Executives\, VPs and Directors of R&D are tackling the most pressing industry challenges and seizing new growth opportunities. Whether an executive\, investor\, researcher or healthcare professional\, this meeting offers an empowering environment that allows you to make wound care decisions with confidence. \nTo know more visit: www.advancedwoundcareusa.com
URL:https://www.pharmajournalist.com/event/advanced-wound-care-summit/
LOCATION:Boston\, MA (Venue TBD)
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220715
DTEND;VALUE=DATE:20220717
DTSTAMP:20260515T164606
CREATED:20220126T093119Z
LAST-MODIFIED:20220126T093119Z
UID:32975-1657843200-1658015999@www.pharmajournalist.com
SUMMARY:RNA Therapeutic Modalities Summit USA
DESCRIPTION:The RNA Therapeutic Modalities Summit is North America’s only industry led conference covering clinical progress and commercial scale development for the full spectrum of RNA therapeutic approaches. \nOur agenda will featuring the pioneering biotechs translating current vaccine success into further clinically validated treatments in broader indications using RNA technologies such as antisense oligonucleotides\, aptamers\, small interfering RNAs (siRNAs)\, microRNAs\, and messenger RNA (mRNA). \nThere will be dedicated discussion on the rationale for different mechanisms-of-action\, how to optimise the power and versatility of RNA-based constructs\, and the progress to date in disease indications encompassing neurodegeneration\, metabolic and cardiovascular disorders and various cancers. \nIf your R&D teams are looking to establish a differentiated drug platform through RNA modification and delivery systems\, improve stability\, delivery and durability of current drug candidates\, or enable tissue-specific administration with higher targeting ability and less toxicity\, make sure they secure a place at this hotly anticipated conference. We look forward to welcoming you to Boston for dedicated in-person networking in June! \nTo know more visit: https://hubs.ly/Q012R75G0
URL:https://www.pharmajournalist.com/event/rna-therapeutic-modalities-summit-usa/
LOCATION:Boston\, USA
ORGANIZER;CN="Kisaco Research":MAILTO:Jessica.mockler@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220718
DTEND;VALUE=DATE:20220721
DTSTAMP:20260515T164606
CREATED:20220304T093223Z
LAST-MODIFIED:20220621T095620Z
UID:33445-1658102400-1658361599@www.pharmajournalist.com
SUMMARY:2nd Annual Next Generation Gene Therapy Vectors Summit
DESCRIPTION:Overcome First Generation Gene Therapy Vector Challenges To Guarantee Targeted\, Specific\, Efficient & Safe Gene Delivery \nThe 2nd Next Generation Gene Therapy Vectors Summit is dedicated to overcoming the current immunogenicity\, toxicity and manufacturability challenges facing the field by pioneering the next generation of superior delivery vectors to deliver safe and efficacious gene therapy products. \nIndustry pioneers from cutting edge biopharma and world-leading academic vectorology groups are set to share clinically meaningful insights on how to enhance existing vectors and pioneer radical novel approaches to deliver genes more efficiently and safely. \nSpanning a range of delivery approaches from cutting-edge AAV capsid optimization\, utilizing lenti and other viral vectors\, to innovative non-viral gene therapy approaches\, this comprehensive event will enable you to reduce immunogenicity\, improve tissue targeting\, simplify manufacturing and enhance the safety profile of your approach. \nEverything in gene therapy starts with delivery\, so join this definitive\, niche conference to delve into the details of vector design\, engineering and optimization case studies\, equipping you with the insights required to deliver transformative therapeutics to patients more effectively and safely than ever before. \nTo know more visit: https://ter.li/3mccj3
URL:https://www.pharmajournalist.com/event/2nd-annual-next-generation-gene-therapy-vectors-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220718
DTEND;VALUE=DATE:20220721
DTSTAMP:20260515T164606
CREATED:20220613T095312Z
LAST-MODIFIED:20220613T095312Z
UID:34412-1658102400-1658361599@www.pharmajournalist.com
SUMMARY:LEAP HR Life Sciences East
DESCRIPTION:LEAP HR: Life Sciences East 2022 Conference will be taking place as an in-person event in Boston\, July 18-20. Returning as a physical event for its seventh year\, this event will showcase 35+ case studies of how life sciences organizations of all stages and sizes are redefining post-pandemic best practices and turbocharging the employee experience to meet the holistic and previously unmet needs of your in-demand life science workforce. \nThis is a unique chance to take advantage of a combination of plenary sessions\, breakout sessions\, panels and roundtable discussions specifically designed to solve your biggest HR challenges and deliver actionable insights for HR innovation. \nNetwork with 250+ other strategic HR leaders working within life sciences on the East Coast and surrounding areas and join a support network of 500+ life science HR leaders who have previously taken part. \nYou’ll hear from companies such as: Takeda\, Novo Nordisk\, AstraZeneca\, Pfizer\, Alexion Pharmaceuticals\, Regeneron Pharmaceuticals\, Alnylam Pharmaceuticals\, BioNTech\, Ipsen\, Novartis\, PTC Therapeutics\, TCR2 Therapeutics\, Ginkgo BioWorks and more… \nFind out more by visiting the website: https://leap-hr-lifesciences-east.com/
URL:https://www.pharmajournalist.com/event/leap-hr-life-sciences-east/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220725
DTEND;VALUE=DATE:20220728
DTSTAMP:20260515T164606
CREATED:20220526T184152Z
LAST-MODIFIED:20220526T184152Z
UID:34241-1658707200-1658966399@www.pharmajournalist.com
SUMMARY:Cell Therapy Potency Assay Summit
DESCRIPTION:Cell Therapy Potency Assay Summit\, taking place from 25-27 of July in Boston\, will bring together professionals working in analytical development\, quality\, regulatory and process development functions. \nJoin your peers to: \n\nBrainstorm best-in-class approaches to overcome variability in QC\nCompare next gen approaches from cytotoxicity to omics\nDevelop reference standards to benchmark across the industry\nCreate an assay with commercialization in mind.\n\nThis summit will equip you with the tools you need to fast track your regulatory submissions and ease through clinical development. \nYou can view the event guide here: https://ter.li/6a13vg \nSecure your place at the summit here: https://ter.li/zp17ep \nWe are looking forward to welcoming you to Boston this July!
URL:https://www.pharmajournalist.com/event/cell-therapy-potency-assay-summit/
LOCATION:The Bostonion\, 26 North Street\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220729
DTSTAMP:20260515T164606
CREATED:20220407T101301Z
LAST-MODIFIED:20220413T091417Z
UID:33748-1658793600-1659052799@www.pharmajournalist.com
SUMMARY:3rd Gamma Delta T Therapies Summit
DESCRIPTION:The data has dropped and 2022 has been touted as a monumental year for γδT Therapies \nWith Adicet Bio\, In8Bio\, Gamma Delta Therapeutics\, Lava Therapeutics\, and ImCheck Therapeutics releasing clinical data from engineered and antibody-based γδT Therapy in patients; the race to market for the first allogeneic and solid tumor-targeting γδT Therapy is truly on. \nJoin the 3rd Gamma Delta T Therapies Summit to learn and network with 120+ of the world’s leaders including γδT pioneer\, Adrian Hayday\, and together accelerate the development of effective\, persistent\, globally accessible cell therapy for solid tumors. \nTake a look at the official program here. \nEnhance cytotoxicity\, discover novel targets\, engineer stealth and persistence\, interrogate cell subsets\, and scale-up manufacturing through a deep understanding of the fundamental biology and target product profile for γδT therapies. \nIndustry experts agree that this year\, the γδT is the cell to know. Ensure you and your team are ahead of the curve and equipped with the need-to-know insights to advance successful therapeutics\, across 2 dedicated tracks covering Discovery\, Process Research\, Preclinical\, and Clinical Development; as well as 3 deep-dive workshops\, and a Gamma Delta 101 Bootcamp.
URL:https://www.pharmajournalist.com/event/3rd-gamma-delta-t-therapies-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220729
DTSTAMP:20260515T164606
CREATED:20220407T101551Z
LAST-MODIFIED:20220413T091500Z
UID:33751-1658793600-1659052799@www.pharmajournalist.com
SUMMARY:3rd Annual B & T Cell-Mediated Autoimmune Disease Drug Development Summit
DESCRIPTION:The 3rd Annual B & T Cell-Mediated Autoimmune Disease Drug Development Summit is the only industry-led forum focused on the therapeutic opportunity of drugs directed against B-cell\, plasma cell\, and T-cell targets in autoimmunity. \n \nSeveral drug approvals for B-cell directed therapies have made waves in autoimmune drug development. As investment and industry momentum increases\, this summit will once again unite the movers and shakers of the B&T cell-mediated autoimmune space with the likes of Pfizer\, Nurix\, Regeneron\, Gossamer Bio\, and more. \nTake a look at the 2022 program here. \nAttending this summit is a unique opportunity to be involved in interactive discussions on: \n\nOvercoming challenges of heterogeneity of disease models and demonstrating B cell activation in tissues\nEmerging therapies including B-cell specific therapies\, tolerizing approaches\, small molecule drugs\, engineered cell immunotherapy\, B&T cell checkpoint targeting\, FcRn inhibition\, as well as PROTAC/degrader approaches\nTherapeutic opportunities across both peripheral and tissue specific autoimmune diseases\nOvercoming clinical challenges of treating B&T cell mediated autoimmune diseases through combinatorial regimens that target T-cell co-stimulation\, leveraging autoantibody signatures to identify patient responders and discussing autoimmune disease biomarkers\n\nAs the space grapples with translational and early clinical drug development challenges\, join this comprehensive forum 80+ key leaders and decision-makers to harness the immune system and conquer B&T cell mediated autoimmune diseases.
URL:https://www.pharmajournalist.com/event/3rd-annual-b-t-cell-mediated-autoimmune-disease-drug-development-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220730
DTSTAMP:20260515T164606
CREATED:20220425T085640Z
LAST-MODIFIED:20220425T085640Z
UID:33898-1658793600-1659139199@www.pharmajournalist.com
SUMMARY:Cytokine-Based Drug Development Summit
DESCRIPTION:The 3rd Cytokine-Based Drug Development Summit has been developed following extensive research to address YOUR biggest challenges in the cytokine field. \nWith 30+ expert speakers\, including the hottest academic researchers and leading figures from the industry\, this 4-day program is your opportunity to gain insight into the latest clinical advancement and have thought provoking discussions around how to overcome the fields greatest drug development challenges. \nWhat can you expect to see? \n\nFurther your understanding of the underlying mechanisms of action\, and T-cell exclusion from the tumor in order to turn cold tumors ‘hot’ with Ask-Gene Pharma\nOptimize cytokine engineering to ensure stability and improve the favorable risk benefit profile with Proviva Therapeutics\nLeverage insights from industry’s leading lights to overcome toxicity challenges by ensuring tumor targeting is selective and therefore enhances the anti-tumor response with Equilium\, Cytonus Therapeutics & Cytimmune\nTake a deep dive into preclinical cancer models covering both in vitro and in-vivo studies and how these are unveiling the most favoured pharmaceuticals properties of therapeutic cytokines with Astra Zeneca & Xilio Therapeutics\nUncover the latest data coming out of the clinic of cytokines in combination with checkpoint inhibitors and monoclonal antibodies with Alkermes & NeoImmune Tech\n\nGet your copy of the brand-new agenda for the full list of speakers and sessions.
URL:https://www.pharmajournalist.com/event/cytokine-based-drug-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220729
DTSTAMP:20260515T164606
CREATED:20220509T102858Z
LAST-MODIFIED:20220509T102858Z
UID:34021-1658793600-1659052799@www.pharmajournalist.com
SUMMARY:2nd Annual mRNA-Based Therapeutics Summit
DESCRIPTION:Do you want to be part of the largest gathering of mRNA professionals? \nThe 2nd Annual mRNA-Based Therapeutics Summit is returning in-person to Boston this July 26-28. \nExpect exclusive data from the movers and shakers in mRNA vaccine and therapy development\, 75+ world-class speakers\, 5 dedicated tracks of content and 45+ deep-dive case studies. Find out more in the full event guide: https://ter.li/yc800m \nHere’s a snapshot of the expert speakers you can hear from: \n\n​​​​Kathy Fernando\, VP\, Head of Worldwide Research\, Development and Medical Operations & Head of mRNA Scientific Planning\, Pfizer\nRegis Gervier\, Global Head\, mRNA Center of Excellence\, Sanofi\nRituparna Das\, VP – COVID Vaccines\, Moderna\nHao Chen\, Global Head of Cell & Viral Drug Substance\, GlaxoSmithKline\nJoe Payne\, Founder\, President & CEO\, Arcturus Therapeutics\nPervin Anklesaria\, Deputy Director\, HIV Vaccines & Biologics\, Bill & Melinda Gates Foundation\nManmohan Singh\, SVP – Pharmaceutical Sciences & Delivery Technologies\, Beam Therapeutics\nAkhilesh Bhambhani\, Senior Director – Biologics Drug Product Development; Tech Dev/Tech Ops\, Ultragenyx\nLiang Shang\, Senior Scientist – Vaccine Analytical\, Merck\nRussell Johnson\, VP – Formulation Research\, RVAC Medicines\nTamar Grossman\, Global Head – RNA & Targeted Therapeutics\, The Janssen Pharmaceutical Companies of Johnson & Johnson\n\nDownload the official brochure to discover why Sanofi\, Ultragenyx\, Beam Therapeutics\, Pfizer\, Moderna\, Merck\, Eli Lilly\, GSK\, and 300+ others have already secured their places.  https://ter.li/yc800m
URL:https://www.pharmajournalist.com/event/2nd-annual-mrna-based-therapeutics-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220729
DTSTAMP:20260515T164606
CREATED:20220518T092848Z
LAST-MODIFIED:20220518T092848Z
UID:34131-1658793600-1659052799@www.pharmajournalist.com
SUMMARY:iPSC Manufacturing Summit
DESCRIPTION:With iPSCs exhibiting game-changing potential in the bid to develop an off-the-shelf therapy\, the brand-new iPSC Manufacturing Summit is the only summit dedicated to solving the manufacturing\, quality and analytical challenges hindering your iPSC-derived treatments from reaching patients. \nThis forum will unite the exclusive community advancing the production of high-quality and consistent iPSC products\, with in depth case studies aimed to develop optimal differentiation\, cryopreservation\, and analytical protocol to enhance process development to ensure it is robust\, rapid and repeatable. \nOur 17+ expert speakers will be addressing methods to enhance potency testing and cell characterization\, enhance iPSC product quality\, and integrate successful gene-editing into your manufacturing. \nTake a look at the full event guide to learn more.
URL:https://www.pharmajournalist.com/event/ipsc-manufacturing-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220729
DTSTAMP:20260515T164606
CREATED:20220526T182248Z
LAST-MODIFIED:20220526T182344Z
UID:34229-1658793600-1659052799@www.pharmajournalist.com
SUMMARY:Targeted Radiopharmaceuticals Summit US (TRP US)
DESCRIPTION:The brand-new Targeted Radiopharmaceuticals Summit US (TRP US) is the only industry-led meeting dedicated to developing next-generation radioligands. The TRP sector has developed dramatically over the previous 18 months\, with a wave of new investment in light of Lutathera’s extraordinary performance. \nAre you part of a pharmaceutical business aiming to have their Theranostic approved? If so\, this agenda is designed to deliver you a well-rounded and complete understanding of the fast-paced radiopharmaceutical sector while also learning about the critical function of diagnostic imaging. \nHear the latest insights\, case studies\, and novel data to help accelerate the development of next-generation radioligand therapies from clinical approval to commercialization. This is the only in-person meeting to bring the discussion around the challenges and opportunities facing developers of Theranostic radioligand therapies. \nTo know more visit: https://ter.li/jtzz4q
URL:https://www.pharmajournalist.com/event/targeted-radiopharmaceuticals-summit-us-trp-us/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220823
DTEND;VALUE=DATE:20220826
DTSTAMP:20260515T164606
CREATED:20220526T184543Z
LAST-MODIFIED:20220526T184543Z
UID:34247-1661212800-1661471999@www.pharmajournalist.com
SUMMARY:Cell Therapy Analytical Development Summit Europe
DESCRIPTION:Cell Therapy Analytical Development Summit Europe\, taking place from 23-25 of August in London\, will bring together professionals working in CMC\, QC\, process development\, and regulatory functions. \nJoin your peers in person to: \n\nLearn to develop a successful potency assay to determine product activity\nExplore reference standards for state-of-the-art analytical development\nDiscover new technology to expand and improve your analytical toolbox\nDevelop and validate analytical methods to fulfil GMP guidelines\nStreamline final product characterisation by starting with the end in mind\n\nYou can view the event guide here: https://ter.li/nxuxfd \nSecure your place at the summit here: https://ter.li/551w6c \nWe are looking forward to welcoming you to London this August!
URL:https://www.pharmajournalist.com/event/cell-therapy-analytical-development-summit-europe/
LOCATION:Hilton London Paddington\, 146 Praed St\, London\, W2 1EE\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220829
DTEND;VALUE=DATE:20220902
DTSTAMP:20260515T164606
CREATED:20220527T124300Z
LAST-MODIFIED:20220527T124300Z
UID:34298-1661731200-1662076799@www.pharmajournalist.com
SUMMARY:6th IPF Summit
DESCRIPTION:With two approved therapeutics and the field working to develop the next generation of IPF drugs\, the opportunity to become the undisputed\, most effective\, and disease-modifying agent on the market has never been greater. \nFrom repairing and regenerating lung tissue to illuminating innovative clinical trial design and advance scientific progress; the 6th IPF Summit is your one-stop-shop to supercharge IPF research and drug development. \nWhat’s new and unmissable for 2022: \n\n29 brand new industry speakers\, as well as returning KOLs including Fernando Martinez\, Naftali Kaminski\, Toby Maher\, and many more\n6 interactive workshops to delve into IPF’s hottest topics\, discuss challenges\, pose your burning questions to leading experts\, and highlight the respiratory pipeline development opportunities including SSc-ILD\, COPD\, and COVID fibrosis\nA brand-new Tissue Repair and Regeneration Day\, with dedicated sessions on halting and reversing disease progression to rethinking senescence to unlocking cell therapies. Get more insight than ever before on evolving basic science and regenerative therapy opportunities\nExclusive presentations on the regulatory and patient perspectives to inform clinical trial design and future therapeutic development\n\nGet in the room with your team to meet peers and KOLs and take away critical insights at the world’s most comprehensive and dedicated IPF conference. Confirmed attendees include AbbVie\, Boehringer Ingelheim\, Bayer\, BMS\, Genentech\, Galecto\, Novartis\, and Trevi Therapeutics. \nFrom navigating pathophysiology and pathobiology\, exploring all available target opportunities to leveraging synthetic control arms in clinical trials; this is a conversation you won’t want to miss to transform your IPF research. \nTo know more visit: https://ter.li/6yo2nd
URL:https://www.pharmajournalist.com/event/6th-ipf-summit/
LOCATION:Westin Boston Seaport District\, 425 Summer St\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220830
DTEND;VALUE=DATE:20220902
DTSTAMP:20260515T164606
CREATED:20220526T182710Z
LAST-MODIFIED:20220526T182710Z
UID:34236-1661817600-1662076799@www.pharmajournalist.com
SUMMARY:2nd Integrin-Targeted Drug Development Summit
DESCRIPTION:Over the last 12 months\, the industry has witnessed promising data and candidates entering the clinic. 7 Hills Pharma\, Corbus Pharmaceuticals\, Vincerx\, and Morphic are paving the way to develop a safe\, efficacious integrins-targeted drug to modify disease biology\, which will be a game-changer for diseases such as oncology\, autoimmune\, and ophthalmology\, with unmet medical needs. \nIn collaboration with leading integrin drug developers\, including Genentech\, 7 Hills Pharma\, and Pfizer\, the 2nd Integrin-Targeted Drug Development Summit is designed for industry leaders to unite and outline clinical strategies for success\, including patient selection biomarkers and dosing. \nGet your critical questions answered to supercharge your clinical programs\, direct your drug pipelines and ensure you take lessons learned to successfully modulate integrins to improve treatment regimens in chronic\, familiar\, and rare diseases.  \nJoin us for this 3-day summit to gain unparalleled insights and experience first-hand from integrin drug developers to accelerate your candidate into the clinic and develop a first-in-class treatment option by modifying underlying disease biology for our patients. \nTo know more visit: https://ter.li/qoq74v
URL:https://www.pharmajournalist.com/event/2nd-integrin-targeted-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220906
DTEND;VALUE=DATE:20220909
DTSTAMP:20260515T164606
CREATED:20220524T085905Z
LAST-MODIFIED:20220524T085905Z
UID:34213-1662422400-1662681599@www.pharmajournalist.com
SUMMARY:Optimizing AAV Safety Summit
DESCRIPTION:Hundreds of clinical trials using AAV are underway\, with several hundred more in preclinical development. Given the sheer volume of studies in the pipeline\, the need to administer high doses\, the clinical holds placed on gene therapy trials\, and regulatory bodies being increasingly stringent on the safety standards they require; it has never been more important to create and implement an AAV safety strategy that’s fit for purpose! \nIn this setting\, the inaugural Optimizing AAV Safety Summit is bringing together key leaders focussed specifically on solving AAV safety challenges across toxicology\, pharmacology\, non-clinical study leads\, clinical development safety specialists and bioanalysis innovators to gain insights on optimizing AAV safety processes and benefit-risk analysis to shorten timelines and prevent potential delays. \nJoin us in Boston alongside key biotech and pharma leaders from the likes of Spark Therapeutics\, Ask Bio\, Eli Lilly\, Takeda\, and more in the AAV space who are prioritizing the development of safe and effective genetic therapies\, learn how clinical safety signals have changed how companies are approaching their pipeline progression\, and gain immediately implementable insights to sharpen your programs currently in preclinical and clinical development. \nTo know more visit: https://ter.li/r92wow
URL:https://www.pharmajournalist.com/event/optimizing-aav-safety-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220906
DTEND;VALUE=DATE:20220909
DTSTAMP:20260515T164606
CREATED:20220713T080736Z
LAST-MODIFIED:20220713T080736Z
UID:34660-1662422400-1662681599@www.pharmajournalist.com
SUMMARY:5th International Cannabinoid-Derived Pharmaceuticals Summit
DESCRIPTION:Over the last half-decade\, we have witnessed game-changing developments within the cannabinoid field\, driving it into a new era of rigorous research\, promising clinical trials and multimillion-dollar deals. Right now\, there are 50 cannabinoid therapeutic trials taking place at phases 2 and 3\, pushing for approval to meet the clinical needs of patients with chronic pain\, cancer\, psychiatric conditions and much more. Despite these positive changes and rapid industry growth there remains key challenges to overcome for drug developers regarding the human evidence gap\, funding and changing regulation – to name just a few. \nThe 5th International Cannabinoid-Derived Pharmaceuticals Summit is uniting drug developers\, investors\, solution providers and academics from around the globe working to overcome these challenges and progress the field of cannabinoid therapeutics. 35+ expert speakers will lead sessions on critical topics across 3 days of presentations\, panel discussions and interactive workshops in Boston. \nAgenda highlights include: \n\nPresent a poster of your drug development pipeline at our investor networking session\, and connect with the decision makers looking to fund promising cannabinoid therapeutics\nGet the most up-to-date regulatory perspectives from the FDA and other organizations with Dominic Chiapperino (FDA) and Cassie Taylor\n(FDA)\nProduce and source high-purity cannabinoids from synthetic\, plant-based and biosynthetic sources with Purisys\, Kinetochem and our other world-leading partners\nHear from the key opinion leaders at the forefront of next-generation cannabinoid-derived pharmaceutical development including Alistair Vickery (Emyria)\, Brian Murphy (Former CEO of Emerald Bioscience) and Jeff Chen (Radicle Sciences)\nStreamline successful late-stage clinical trials and be the next one across the finish line with a multi-format and highly interactive session with Sud Agarwal (Cannvalate)\nJoin 2 half-day workshops – one dedicated to bridging the gap between OTC and prescribed pharmaceuticals\, and an additional behind-the-scenes workshop on the psychedelics field\, preparing you for exploration into a new area\nConnect with 80+ thought leaders and industry peers as they come together to drive discussion and progress across the 3-day event\n\nThe Summit focuses on the real science in the cannabinoid industry and is the only chance to connect with likeminded\, analytical professionals looking to move the dial forward in this exciting space. Check out the event guide for the full agenda
URL:https://www.pharmajournalist.com/event/5th-international-cannabinoid-derived-pharmaceuticals-summit/
LOCATION:Boston\, MA (venue TBC)
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220913
DTEND;VALUE=DATE:20220917
DTSTAMP:20260515T164606
CREATED:20220516T094442Z
LAST-MODIFIED:20220516T094442Z
UID:34110-1663027200-1663372799@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy for Ophthalmic Disorders
DESCRIPTION:Revolutionizing Genetic Therapy Development & Delivery to the Eye \nDiscovering Next Generation Administration Routes for the Eye; Overcoming the Translational Challenges of Ophthalmic Preclinical Models; & Discussing Toxicity & Targeting Challenges of Vector-Based Approaches \nThe ophthalmology field is bursting with novel genetic approaches for targeting many disorders\, with gene therapy taking centre stage as a one-time treatment option. With more invasive subretinal approaches being used in the clinic\, as well as more innovative outpatient methods such as suprachoroidal delivery\, there are a lot of pros and cons to discuss as the field progresses towards developing efficacious and durable treatments for many ophthalmic disorders. \nReturning for its 3rd year\, the Gene Therapy for Ophthalmic Disorders is the definitive forum for those working on ophthalmic gene therapy. This is the only conference that unites pharma and biotech to address the most pressing challenges\, with focus on discussing and sharing solutions with the key leaders in the industry. \nThis year we have expanded into two streams of learning\, putting more emphasis on the individual challenges faced in both the preclinical and clinical phases of ophthalmic gene therapy drug development. \nGene therapy for ophthalmic disorders has only seen one FDA approved therapy\, which drug will be the next? Join 150+ of your peers to discuss and overcome the barriers preventing drugs getting to market. \nLeave the definitive 3rd Annual Gene Therapy for Ophthalmic Disorders forum equipped with knowledge of novel methods and developments\, actionable lessons learned and new connections. Don’t miss your opportunity to be a part the conversation which could lead to the next drug approval.
URL:https://www.pharmajournalist.com/event/3rd-annual-gene-therapy-for-ophthalmic-disorders/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220913
DTEND;VALUE=DATE:20220916
DTSTAMP:20260515T164606
CREATED:20220620T111850Z
LAST-MODIFIED:20220620T111850Z
UID:34473-1663027200-1663286399@www.pharmajournalist.com
SUMMARY:5th Microbiome Movement – Skin Health & Dermatology Summit
DESCRIPTION:Translating Scientific Methodologies Addressing the Skin Microbiome into Commercially Viable Dermatological Therapeutics & Cosmetic Products \nSkin microbiome research is continuing to gain increasing market traction from a number of stakeholders\, including drug developers and cosmetic brands. For investment and progress to continue\, it is vital to meet and connect with the key opinion leaders in the space. \nNow in its fifth year\, the Microbiome Movement – Skin Health & Dermatology Summit will unite the field’s leaders from academia and industry to address the unique scientific and commercial challenges of working in the skin microbiome. This meeting will provide a platform for crucial discussions which will hasten the development of microbiome-targeting therapeutics and cosmetics that focus on characterization\, clinical testing\, and product commercialization. \nThis is your opportunity to connect with 100+ collaborative thought leaders in the skin microbiome field from academics\, drug developers\, cosmeceutical developers\, cosmetic and consumer brands\, to obtain a holistic view of the microbiome dermatology landscape that will revolutionise your product pipeline. \nFind out more about the meeting\, who’s attending and what you could learn by downloading the latest event guide: https://ter.li/nzhrvy \nOr become one of our event partners and showcase your company’s latest technologies and solutions! Get in touch with us directly or request a partnership prospectus here: https://ter.li/9kybuv \nWe look forward to welcoming you to Boston in September!
URL:https://www.pharmajournalist.com/event/5th-microbiome-movement-skin-health-dermatology-summit/
LOCATION:Four Points by Sheraton Boston Logan Airport Revere\, 407 Squire Rd\, Revere\, MA\, 02151\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@microbiome-movement.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220919
DTEND;VALUE=DATE:20220924
DTSTAMP:20260515T164606
CREATED:20220317T083147Z
LAST-MODIFIED:20220317T083147Z
UID:33597-1663545600-1663977599@www.pharmajournalist.com
SUMMARY:7th CAR-TCR Summit
DESCRIPTION:Back to Boston with a bang! With 1\,500 CAR and TCR developers\, 200 speakers\, 150 live presentations\, 20 hours of networking and more surprises in store\, the 7th CAR-TCR Summit will be the BIGGEST ever. \nGain end-to-end insights from industry giants and the innovators bringing disruptive technologies from bench to bedside and from vein to vein. \nDiscuss everything from novel allogeneic approaches with enhanced safety considerations\, the latest in vivo gene engineering techniques\, and advances in CMC and analytics to ensure the development of high-quality cell products. \nWith your industry reuniting in-person for the first time since 2019 to discuss leveraging the powerful potential of iPSC platforms\, learnings from our successes and pitfalls\, and manufacturing automation innovations for large scale consistent production\, you can’t afford to miss the 7th Annual CAR-TCR Summit as we bring you more speakers\, more content and more exclusive insights than ever before! \nTo know more visit: https://ter.li/km5zwy
URL:https://www.pharmajournalist.com/event/7th-car-tcr-summit/
LOCATION:Boston\, MA
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220919
DTEND;VALUE=DATE:20220921
DTSTAMP:20260515T164606
CREATED:20220523T112249Z
LAST-MODIFIED:20220523T112249Z
UID:34202-1663545600-1663718399@www.pharmajournalist.com
SUMMARY:2nd Annual Aseptic Processing Conference
DESCRIPTION:2nd Annual Aseptic Processing Conference  \nConference: 19 – 20 September 2022\nWorkshop: 21 September 2022 \nLondon\, UK\nhttp://www.asepticprocessing.co.uk/PJWL \n \nSponsored by: Dec Group\, Rapid Micro Biosystems\, Raumedic and STERIS\n\nConference Chairman: James Drinkwater\, Head of Aseptic Processing Special Interest Group PHSS and Head of GMP Compliance\, F Ziel GMBH \nDriving a Holistic Approach to Assurance of Product Sterility through Aseptic Manufacturing following QRM Principles \nSAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference\, this year taking place in London\, on the 19 and 20 September 2022. \nThe Aseptic processing industry has seen consistent growth in recent years\, with advances in innovative therapeutics\, the introduction of novel techniques and personnel protocols\, the integration of robotics and automation in filling lines\, and rise of rapid microbiological methods being just a few of the factors driving this growth. \nThe Aseptic Processing equipment market was approaching a valuation of 10 billion USD in 2015\, and is projected to exceed 12 billion USD in value by next year\, then to far surpass a total market value of 50 billion USD before the end of the decade. \nJoin us to discuss and address the  Guidance and Regulation including the EU GMP Annex 1\, environmental control delving into the contamination control strategy\, Pharma moving forward 4.0 covering data integrity and data consistency\, robotics in aseptic processing and exploring the continued aseptic processing development in Annex 1 and environmental monitoring \nThis event is CPD Accredited  \nEvent Hashtag: #AsepticProcessing  \nBenefits of Attending: \n\nDiscuss the revisions and the impact of Annex 1 on aseptic manufacturing\nExplore the applications of rapid micro methods in the manufacture of sterile products\nDiscover a risk-based approach to cleaning and disinfection\nDelve into case studies of competence in global aseptic manufacturing\nUncover the journey of isolation technology in a large biotech pharmaceutical plant\nAnalyse the new abilities of robotics and automation through their integration into aseptic technique\n\n Who Should Attend? \n\nValidation Managers\nSenior Microbiologists\nSenior QA’s and QC’s\nQuality Control Managers\nHeads of GMP Compliance\nQuality Assurance Experts\nTechnical Operations Leads\nLeaders in Sterility Assurance\nCleanroom Managers\nRegulatory Affairs Managers\nProduction Managers\nQuality Systems Managers\nHeads of Quality Compliance\nProcess Leaders\nSenior Auditors\nBioprocess Research & Development\n\n PLUS – Post-Conference Workshop on 21 September 2022… \nImplementation Strategy of Annex 1 in New or Existing Facilities \nLed by: Richard Denk\, Senior Consultant Aseptic Processing & Containment\, Skan AG \nView the brochure and to download visit http://www.asepticprocessing.co.uk/PJWL
URL:https://www.pharmajournalist.com/event/2nd-annual-aseptic-processing-conference/
LOCATION:London\, UK
ORGANIZER;CN="SAE Media Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220919
DTEND;VALUE=DATE:20220921
DTSTAMP:20260515T164606
CREATED:20220524T091925Z
LAST-MODIFIED:20220524T091925Z
UID:34218-1663545600-1663718399@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes San Francisco
DESCRIPTION:SAE Media Group’s 3rd Annual Conference\nSeptember 19 – 20\, 2022 | San Francisco\, CA\, USA\n————————————————————————- \nThe pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to aid self-administration and deliver biologics\, high concentration\, and large-volume drug products. \n \nThis year’s conference will be assessing the latest developments in new technologies for next generation device design\, including computational simulation approaches forming the digital revolution of devices design. Furthermore\, the latest advances in digital combination product development will be explored through the lens of lifecycle management and user-centric combination products. Leading experts from big pharma will be presenting case studies on recent advances in platform approaches in drug delivery devices and smart devices\, while a panel discussion will explore the emerging opportunities of platforms for injectable devices. With recent developments in industry regulations and guidance\, the 2022 agenda will give an international insight into the global regulatory environment and leading FDA representatives will address the key standards to be aware of in injectable device development.  \nOver recent years we have seen the need for injectable devices to adapt to novel therapeutics. Our expert industry thought leaders will present case studies and updates to the industry’s approach to injectable delivery for novel drug products. Furthermore\, our speakers will be assessing the key considerations for primary packaging and CMC approaches to injectable device development.  \nAs part of SAE Media Group’s leading injectable drug delivery portfolio\, this event is not to be missed. \nThe two-day agenda offers you peer-to-peer networking with Global Product Managers\, Senior PFS Engineers\, Device Testing Managers\, Heads of Late-Stage PFS Development and many more. \nTo know more visit: http://www.prefilled-sanfrancisco.com/pharmajournalistwl
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-san-francisco-2022/
LOCATION:Hyatt Centric\, Fisherman’s Wharf\, San Francisco\, CA\, 94133\, United States
ORGANIZER;CN="SAE Media Group":MAILTO:richard.jones@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220920
DTEND;VALUE=DATE:20220923
DTSTAMP:20260515T164606
CREATED:20220519T110535Z
LAST-MODIFIED:20220908T090420Z
UID:34139-1663632000-1663891199@www.pharmajournalist.com
SUMMARY:mRNA Process Development & Manufacturing Summit
DESCRIPTION:The mRNA Process Development & Manufacturing Summit will be taking place in-person in Boston\, MA this month (September 20 – 22\, 2022). The only conference roadmap to accelerate mRNA drug substance process scale up and manufacturing! \nThis conference will showcase the pioneering work of 30+ global leaders across 3 days of immersive content sharing new data\, allowing you to stay ahead of the curve. \nIf you and your team are looking to learn how to overcome mRNA process scale up and manufacturing hurdles towards regulatory harmonization by optimizing in vitro transcription\, purification\, and analytical validation of your mRNA drug substance\, then you should attend this dedicated industry forum to see the outlook to this advancing and dynamic field. \nMultiple functions from 75+ leading companies and their teams have already registered\, here’s just a snapchat: \n\nDirector – Business Development mRNA Therapeutics\nSenior Director – Manufacturing Science & Technology\nHead of Quality\nPrincipal Applications Scientist – mRNA\nDirector – Formulation and Drug Delivery\nPrincipal Scientist – Early Bioprocess\nSenior Process Development Associate – mRNA\nGroup Leader (RNA Reagents) – Production\nDownstream Scientist – Technical R&D\nScientist II – Analytical Development\nDirector – RNA Therapeutics Development R & D\nDirector – CMC RNA Vaccines Biopharmaceutical Development\nAssociate Director – Drug Substance\nSenior Director – CMC Reg Affairs Regulatory\n\nWith very limited passes remaining\, register today and be part of the conversation. \nTo know more visit: https://ter.li/9v5h9k
URL:https://www.pharmajournalist.com/event/mrna-process-development-manufacturing-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220920
DTEND;VALUE=DATE:20220923
DTSTAMP:20260515T164606
CREATED:20220607T100621Z
LAST-MODIFIED:20220607T100621Z
UID:34368-1663632000-1663891199@www.pharmajournalist.com
SUMMARY:2nd NSCLC Drug Development Summit
DESCRIPTION:Advances in molecular and immunohistochemical techniques have ushered the NSCLC space into an exciting era of personalized medicine and improved outcomes – and a plethora of novel therapies are now in clinical development. Despite this\, and whether patients fit into one of the actionable alteration subtypes of NSCLC or not\, most will progress and/or develop resistance to currently available treatments. \nNSCLC remains one of the highest tumor indications of unmet clinical need\, with prevalence only set to increase. Focusing from late-line through to early-line\, this conference will address how to supercharge your pipeline through implementing smart drug design; expert translational medicine; advanced trial design and patient recruitment; and evidence-based combination and sequencing rationale specific to NSCLC. \nThe 2nd NSCLC Drug Development Summit returns as the only industry-led forum for large biopharma\, biotech and academic leaders to address mechanisms of drug resistance\, spearhead progress in molecular subtyping and define practice-changing drug sequencing and combinations for the largest solid tumor indication. \nWe will be focusing on: \n\nRefining molecular testing of NSCLC tumors and making next-generation sequencing tools more accessible in the clinical setting\nInvestigating novel immune checkpoints and checkpoint inhibitor sequencing or combinations with surgery\, chemo and/or radiotherapy where applicable\, to define therapeutic options with better safety and efficacy outcomes in second line or beyond\nOvercoming resistance mechanisms and patient progression after TKI treatment approaches for NSCLC tumors with actionable alterations\nProviding clarity on tumor biopsy testing guidelines to promote effective personalized treatment of patients\nIdentifying truly transformative investigational drugs for use in the early vs. late-stage NSCLC setting and cut through the noise of increasingly complex therapeutic options\nExploring trial design challenges to watch out for and tips for patient inclusion/exclusion criteria\n\nJoin the NSCLC Summit for 3 jam-packed days of presentations\, panel discussions and interactive workshops with over 20 expert industry speakers. \nThere has never been a more important time to rally together to defeat NSCLC and radically change patients lives. \nTo know more visit: https://bit.ly/3mpftud
URL:https://www.pharmajournalist.com/event/2nd-nsclc-drug-development-summit/
LOCATION:Boston\, MA (venue TBC)
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220920
DTEND;VALUE=DATE:20220922
DTSTAMP:20260515T164606
CREATED:20220720T075747Z
LAST-MODIFIED:20220720T075747Z
UID:34728-1663632000-1663804799@www.pharmajournalist.com
SUMMARY:Reuters Events: Cell & Gene Therapy USA 2022
DESCRIPTION:Co-create a commercial toolkit that enables suitable\, scalable and sustainable growth.  \nWith over 20 CGTs projected to be approved by 2025\, it’s clear that there are huge commercial and medical opportunities for precision medicine. But despite this unprecedented growth\, unstable infrastructure\, lack of standardization and novel scientific nuance means that there is still no industry blueprint for successful commercialization. \nTo realize this potential\, precision medicine trailblazers must share lessons of launch success and overcome pain points to allow pharma to reinforce frameworks across manufacturing\, market access and reimbursement to build infallible launch strategies across the board. Commercialization networks must go even further\, transforming our healthcare system to guarantee scalable and sustainable growth.     \nDon’t get left behind.   \nJoin us at Reuters Events: Cell and Gene Therapy USA where we have leaders from industry front runners to share their successes and pitfalls. With 30+ speakers\, 5 case-studies and over 1500+ fellow CGT attendees – we will pioneer a new gold standard for commercialization\, readying the world for CGT as a frontline treatment. \nTo know more visit: https://bit.ly/3oepDP3
URL:https://www.pharmajournalist.com/event/reuters-events-cell-gene-therapy-usa-2022/
LOCATION:Virtual
ORGANIZER;CN="Reuters Events":MAILTO:daisy.beale@thomsonreuters.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220921
DTEND;VALUE=DATE:20220923
DTSTAMP:20260515T164606
CREATED:20220404T083554Z
LAST-MODIFIED:20220404T083554Z
UID:33687-1663718400-1663891199@www.pharmajournalist.com
SUMMARY:Oligonucleotide Therapeutics and Delivery Conference 2022
DESCRIPTION:Part of the 13th annual RNA Therapeutic series of events\nSMi’s 2nd Annual Conference \nOligonucleotide Therapeutics and Delivery Conference 2022\nDate: 21st – 22nd September 2022\nLocation: London\, UK\nWebsite: www.oligonucleotide.co.uk/PharmaJournalist \nAdvancements in extra-hepatic delivery of oligonucleotides \nThe Oligonucleotide Therapeutics and Delivery conference reveals the latest in oligonucleotide discovery and delivery\, with presentations on targeted delivery mechanisms\, oligonucleotide chemistries and important clinical advances. Global experts from big pharma and leading biotechs will explore the emerging therapeutic applications of oligonucleotides with case studies surrounding the discovery and development of oligonucleotide therapeutics as well as CMC and regulatory standpoints. The two-day conference will bring you high-quality insights and industry connections on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY. \nEstablished on the success of our RNA Therapeutics series\, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments. \nBenefits of attending: \n\nListen to case studies presenting on pre-clinical and clinical research in areas such as oncology and what can be learned for future clinical trials\nDeepen your understanding of oligonucleotide therapeutic delivery and explore the latest innovations in extrahepatic oligonucleotide delivery and target specificity\nUnderstand the regulatory and CMC environment surrounding oligonucleotide therapeutic development\nExplore developments in oligonucleotide chemistries and examine developments in novel applications of antisense oligonucleotides and siRNA\nEngage in the latest innovations in oligonucleotide therapeutics such as utilising AI machine learning to drive the discovery of novel therapeutics\n\nPlus\, two interactive half day pre-conference workshops on 20th September 2022: \n\nOligonucleotide Therapies- Overcoming The Challenges Of Delivery led by Nick Lench\, Executive Director\, NATA\, Martin Kerr\, Head of Business Development & Partnerships\, Nucleic Acid Therapy Accelerator\, Ritwick Sawakar\, MRC Investigator\, MRC Toxcology Unit\, University Of Cambridge\nManaging CMC Activities For The Development Of Oligonucleotide Therapeutics led by Mia Kiistala\, CEO/Owner/Principal Consultant\, Aurora CMC Consulting \n\nCHAIRS FOR 2022: \n\nEkkehard Leberer\, Senior Life Sciences Consultant\, Elbicon\njimmy Weterings\, Principal Scientist\, AstraZeneca \n\nFEATURED 2022 SPEAKERS INCLUDE:  \n\nShalini Anderson\, Vice President Oligonucleotide Discovery\,AstraZeneca\nHeinrich Haas\, Vice President RNA Formulation & Drug Delivery\, BioNTech\nTamar Grossman\, Global Head of RNA and Targeted Therapeutics\, Janssen pharmaceuticals\nSarahTabrizi\,Director of UCL Huntington’s disease centre\, UCL Institute of Neurology\nMacarena Hernandez-Jimenez\, Chief Scientific Officer\, AptaTargets\nDavid Evans\, Chief Scientific Officer\, Sirnaomics\nNick Lench\, Executive Director\, Nucleic Acid Therapy Accelerator\nBart Anderson\,Senior Director of R&D\, Exicure\n\nWho should attend: \nExecutives\, Directors\, VPs\, Heads\, Principals\, Managers of: \n\nRNA Biology/Discovery\nNovel Therapeutic Modalities\nInnovation Technologies\nC-level Scientific Executives\nFormulation and Drug Delivery\nClinical Research and Development\nCell Biology\n\nEARLY-BIRD RATES: \n\nBOOK BY 29TH APRIL AND SAVE £400\nBOOK BY 31ST MAY AND SAVE £300\nBOOK BY 30TH JUNE AND SAVE £200\n\nAdditional Contact Info: \nT: +44 (0)20 7827 6154 \nE: ngaloria@smi-online.co.uk \nLinkedIn: SMi Pharma \nTwitter: @SMiPharma | #SMiOligonucleotides  \nKeywords: \nSmall interfering RNA\, siRNA\, Antisense therapy\, DNA\, RNA\, nucleic acid\, mRNA\, Micro RNA\, RNA-induced silencing complex\, RISC\, Aptamers\, oligonucleotide\, peptide molecules\, Immunogenicity\, Drug pipeline\, short interfering RNA\, silencing RNA\, RNA interference\, RNAi\, mRNA degradation \nHashtags:  \n#SmallinterferingRNA\, #siRNA\, #Antisensetherapy\, #DNA\, #RNA\, #nucleicacid\, #mRNA\, #MicroRNA\, #RNAinducedsilencingcomplex\, #RISC\, #Aptamers\, #oligonucleotide\, #peptidemolecules\, #Immunogenicity\, #Drugpipeline\, #shortinterferingRNA\, #silencingRNA\, #RNAinterference\, #RNAi\, #mRNAdegradation
URL:https://www.pharmajournalist.com/event/oligonucleotide-therapeutics-and-delivery-conference-2022/
LOCATION:London\, UK
ORGANIZER;CN="SMi Events":MAILTO:ngaloria@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220926
DTEND;VALUE=DATE:20220929
DTSTAMP:20260515T164606
CREATED:20220531T070301Z
LAST-MODIFIED:20220531T070301Z
UID:34307-1664150400-1664409599@www.pharmajournalist.com
SUMMARY:4th RAS-Targeted Drug Development Summit
DESCRIPTION:For decades\, RAS has existed as an elusive therapeutic target\, and drugging this high-value oncogene was deemed impossible. Despite this\, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is\, in fact\, druggable and that drugging this protein unlocks a world of successful therapeutic interventions. The future looks bright for treating patients with cancers harboring the RAS mutation. \nThe 4th RAS-Targeted Drug Development Summit returns as the definitive industry dedicated forum for the whole community of individuals committed to targeting RAS. Bigger and better than ever before\, we will unite 300+ experts to showcase 3-days of exclusive\, never shared before data as we delve into accelerating discovery and emerging strategies\, optimizing translation and pre-clinical development\, and advancing the landscape of clinical trials for combinations and monotherapies. \nWith mounting success in targeted RAS drugs\, leading frontiers and experts must unite and continue accelerating the applications of this therapeutic for patients in need.  Through novel data\, expert insight\, and exclusive discussions with global leaders\, we will facilitate vital learnings to progress RAS therapeutics to drug all-mutations from G12C\, G12D\, and G12V. Continuing to advance valuable combination therapies into the clinic\, and finally\, crack resistance to RAS targeted therapeutics. \nAccess the official agenda for more information. \nEarly-bird & team discounts available – Secure your place today.
URL:https://www.pharmajournalist.com/event/4th-ras-targeted-drug-development-summit/
LOCATION:Marriott Burlington\, One Burlington Mall Road\, Burlington\, MA\, 01803\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR